Hannah Slater | Authors

March 04, 2021

“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.

March 03, 2021

In this study, investigators sough to determine the incidence of CRLF2 rearrangements and IKZF1 deletions in Hispanic versus non-Hispanic children with B-cell acute lymphoblastic leukemia.

March 03, 2021

Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy in patients with HPV-related oropharyngeal cancers.

March 03, 2021

In a phase 2 study, adavosertib plus gemcitabine showed signs of activity in platinum-resistant or platinum-refractory advanced high-grade serous ovarian cancer, including rare histological subtypes of ovarian cancer.

March 02, 2021

“Our results support further study of serial molecular imaging along with combined [histone deacetylase inhibitors; HDACi] and [aromatase inhibitor; AI] therapy (such as ECOG-ACRIN study E2112), to further delineate the role of HDACi and potential biomarkers in AI-refractory ER+ advanced breast cancer,” wrote the study authors.

March 02, 2021

“The [phase 1b/2] data [are] promising and support the current phase 3, multicenter trial, which we hope will lead to FDA approval and a new much-needed treatment option for this patient population,” said David Sallman, MD.

March 01, 2021

“Emerging evidence supports a possible role for overall dietary patterns that, in totality, emphasize habitually consuming fruits, vegetables, grains, and low-fat dairy and reducing red meat and alcohol intake,” wrote the study authors.

February 27, 2021

Given these study findings, investigators suggested that future efforts should address racial/ethnic, educational, financial, and geographic barriers to receiving digital breast tomosynthesis screening at the facility level.

February 26, 2021

“These updated results from the phase 2 MERECA trial underscore the positive impact on overall survival that ilixadencel may achieve for [patients with kidney cancer],” said Sven Rohmann, MD, PhD.

February 25, 2021

According to investigators, study findings could help guide treatment decisions and future research, as well as suggest new biomarkers for exploration.